04:58 PM EDT, 10/02/2024 (MT Newswires) -- Spero Therapeutics ( SPRO ) said Wednesday that results from a phase 1 trial evaluating the safety and intrapulmonary pharmacokinetics of SPR719 back its further investigation to treat non tuberculous mycobacterial-pulmonary disease, or NTM-PD.

"Effective oral therapy for NTM lung disease requires adequate uptake into the pulmonary epithelial lining fluid and alveolar macrophages, where mycobacteria reside and proliferate. The results of this Phase 1 study suggest that SPR719 (the active moiety of SPR720) had significant lung uptake and enhanced concentrations in these compartments," said Spero Chief Executive Sath Shukla.

Price: 1.3500, Change: +0.04, Percent Change: +3.05